読み込み中
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
前日終値
$1.39
+$0.11 · +8.59%
日中の時刻はETです。市場データは遅延する場合があります。
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
日中レンジ
現在 $1.39
52週レンジ
現在 $1.39
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
46
適正価値
センチメント
59
まちまち
リスク
68
高リスク
モメンタム
74
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
日中レンジ
現在 $1.39
52週レンジ
現在 $1.39
営業利益
純利益
| 指標（USD） | 2026年度 | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|---|
| 売上原価 | — | 22.94万 USD | — | — | — |
| 粗利益 | — | −22.94万 USD | — | — | — |
| 研究開発 | 1396.24万 USD | 926.67万 USD | 2310.04万 USD | 3329.95万 USD | 1725.83万 USD |
| 販売・一般管理 | 851.1万 USD | 857.01万 USD | — | 1155.16万 USD | — |
| 営業費用 | 2265.17万 USD | 1783.68万 USD | 3217.96万 USD | 4508.04万 USD | 2725.3万 USD |
| 受取利息 | 59.68万 USD | 85.3万 USD | 113.67万 USD | 56.23万 USD | 4.41万 USD |
| 支払利息 | 1.79万 USD | 33.27万 USD | 289.39万 USD | 430.02万 USD | 216.3万 USD |
| 減価償却費と償却費 | 17.83万 USD | 22.94万 USD | 22.94万 USD | 22.94万 USD | 22.94万 USD |
| 営業利益 | −2265.17万 USD | −1806.62万 USD | −3217.96万 USD | −4508.04万 USD | −2725.3万 USD |
| 純利益 | −2207.29万 USD | −1754.21万 USD | −3212.05万 USD | −5025.58万 USD | −2608.45万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
